Variant Synonymizer: Platform to identify mutations defined in different ways is available now!
Over 2,000 gene–disease validation summaries are now available—no login required!
VSX2 variants underlie autosomal recessive microphthalmia, with homozygous and compound heterozygous alleles reported in at least four unrelated probands ([PMID:24033328]; [PMID:31884615]; [PMID:37628625]; [PMID:30181649]). Reported variants include the missense change c.667G>C (p.Gly223Arg) ([PMID:24033328]) and frameshift alleles such as c.422delA (p.Asn141IlefsTer19) ([PMID:31884615]). Affected individuals present bilateral reduction in ocular globe size with variable additional anterior segment anomalies.
Functional studies demonstrate that loss of VSX2 function causes microphthalmia. The Vsx2LacZ knock-in/knock-out mouse allele recapitulates bilateral microphthalmia, disrupted retinal layering, delayed neurogenesis, and absence of bipolar interneurons, confirming a recessive loss-of-function mechanism ([PMID:38895315]; [PMID:39610658]). Targeted mouse knock-ins of homeodomain and CVC domain mutations abolish high-affinity DNA binding and phenocopy the null phenotype, establishing the critical role of these domains in ocular development ([PMID:23028343]).
Key Take-home: VSX2 genetic testing is clinically actionable for autosomal recessive microphthalmia diagnosis and counseling.
Gene–Disease AssociationLimited4 probands across 4 publications; minimal segregation data Genetic EvidenceLimitedReported in four unrelated probands with missense and frameshift variants; no extended familial segregation Functional EvidenceStrongMultiple knock-in/knock-out mouse models recapitulate microphthalmia and confirm loss-of-function |